vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and Albemarle Corporation (ALB). Click either name above to swap in a different company.
Albemarle Corporation is the larger business by last-quarter revenue ($1.4B vs $829.0M, roughly 1.7× Acadia Healthcare Company, Inc.). Acadia Healthcare Company, Inc. runs the higher net margin — 0.5% vs -29.0%, a 29.5% gap on every dollar of revenue. On growth, Albemarle Corporation posted the faster year-over-year revenue change (15.9% vs 7.5%). Over the past eight quarters, Albemarle Corporation's revenue compounded faster (2.4% CAGR vs 2.0%).
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers...
ACHC vs ALB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $829.0M | $1.4B |
| Net Profit | $4.5M | $-414.2M |
| Gross Margin | — | 13.9% |
| Operating Margin | — | -15.2% |
| Net Margin | 0.5% | -29.0% |
| Revenue YoY | 7.5% | 15.9% |
| Net Profit YoY | -50.8% | -650.1% |
| EPS (diluted) | $0.05 | $-3.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $829.0M | — | ||
| Q4 25 | $821.5M | $1.4B | ||
| Q3 25 | $851.6M | $1.3B | ||
| Q2 25 | $869.2M | $1.3B | ||
| Q1 25 | $770.5M | $1.1B | ||
| Q4 24 | $774.2M | $1.2B | ||
| Q3 24 | $815.6M | $1.4B | ||
| Q2 24 | $796.0M | $1.4B |
| Q1 26 | $4.5M | — | ||
| Q4 25 | $-1.2B | $-414.2M | ||
| Q3 25 | $36.2M | $-160.7M | ||
| Q2 25 | $30.1M | $22.9M | ||
| Q1 25 | $8.4M | $41.3M | ||
| Q4 24 | $32.6M | $75.3M | ||
| Q3 24 | $68.1M | $-1.1B | ||
| Q2 24 | $78.5M | $-188.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -7.7% | ||
| Q2 24 | — | -0.7% |
| Q1 26 | — | — | ||
| Q4 25 | -142.4% | -15.2% | ||
| Q3 25 | 4.7% | -16.6% | ||
| Q2 25 | 5.8% | 3.6% | ||
| Q1 25 | 1.7% | 1.8% | ||
| Q4 24 | 4.9% | 0.4% | ||
| Q3 24 | 12.1% | -81.9% | ||
| Q2 24 | 13.4% | -34.4% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | -143.3% | -29.0% | ||
| Q3 25 | 4.3% | -12.3% | ||
| Q2 25 | 3.5% | 1.7% | ||
| Q1 25 | 1.1% | 3.8% | ||
| Q4 24 | 4.2% | 6.1% | ||
| Q3 24 | 8.4% | -78.9% | ||
| Q2 24 | 9.9% | -13.2% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-12.98 | $-3.88 | ||
| Q3 25 | $0.40 | $-1.72 | ||
| Q2 25 | $0.33 | $-0.16 | ||
| Q1 25 | $0.09 | $0.00 | ||
| Q4 24 | $0.36 | $0.29 | ||
| Q3 24 | $0.74 | $-9.45 | ||
| Q2 24 | $0.85 | $-1.96 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $158.5M | — |
| Total DebtLower is stronger | $2.5B | $3.2B |
| Stockholders' EquityBook value | $2.0B | $9.5B |
| Total Assets | $5.5B | $16.4B |
| Debt / EquityLower = less leverage | 1.29× | 0.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $158.5M | — | ||
| Q4 25 | $133.2M | — | ||
| Q3 25 | $118.7M | $1.9B | ||
| Q2 25 | $131.4M | $1.8B | ||
| Q1 25 | $91.2M | $1.5B | ||
| Q4 24 | $76.3M | $1.2B | ||
| Q3 24 | $82.1M | $1.7B | ||
| Q2 24 | $77.2M | $1.8B |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $3.2B | ||
| Q3 25 | $2.3B | $3.6B | ||
| Q2 25 | $2.3B | $3.6B | ||
| Q1 25 | $2.2B | $3.5B | ||
| Q4 24 | $2.0B | $3.5B | ||
| Q3 24 | $1.9B | $3.6B | ||
| Q2 24 | $1.8B | $3.5B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $9.5B | ||
| Q3 25 | $3.1B | $10.0B | ||
| Q2 25 | $3.1B | $10.2B | ||
| Q1 25 | $3.0B | $10.0B | ||
| Q4 24 | $3.1B | $10.0B | ||
| Q3 24 | $3.0B | $10.2B | ||
| Q2 24 | $3.0B | $11.2B |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.5B | $16.4B | ||
| Q3 25 | $6.4B | $17.1B | ||
| Q2 25 | $6.3B | $17.3B | ||
| Q1 25 | $6.1B | $17.0B | ||
| Q4 24 | $6.0B | $16.6B | ||
| Q3 24 | $5.9B | $17.5B | ||
| Q2 24 | $5.7B | $18.4B |
| Q1 26 | 1.29× | — | ||
| Q4 25 | 1.28× | 0.33× | ||
| Q3 25 | 0.74× | 0.36× | ||
| Q2 25 | 0.74× | 0.35× | ||
| Q1 25 | 0.72× | 0.35× | ||
| Q4 24 | 0.64× | 0.35× | ||
| Q3 24 | 0.62× | 0.35× | ||
| Q2 24 | 0.62× | 0.31× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $61.5M | $388.5M |
| Free Cash FlowOCF − Capex | — | $233.1M |
| FCF MarginFCF / Revenue | — | 16.3% |
| Capex IntensityCapex / Revenue | — | 10.9% |
| Cash ConversionOCF / Net Profit | 13.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $692.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.5M | — | ||
| Q4 25 | $-86.3M | $388.5M | ||
| Q3 25 | $73.2M | $355.6M | ||
| Q2 25 | $133.5M | $-7.2M | ||
| Q1 25 | $11.5M | $545.4M | ||
| Q4 24 | $116.7M | $674.0K | ||
| Q3 24 | $163.1M | $240.5M | ||
| Q2 24 | $171.1M | $362.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-179.5M | $233.1M | ||
| Q3 25 | $-63.0M | $223.4M | ||
| Q2 25 | $-34.2M | $-126.8M | ||
| Q1 25 | $-163.2M | $362.8M | ||
| Q4 24 | $-86.8M | $-355.1M | ||
| Q3 24 | $-27.1M | $-62.6M | ||
| Q2 24 | $16.9M | $-84.7M |
| Q1 26 | — | — | ||
| Q4 25 | -21.8% | 16.3% | ||
| Q3 25 | -7.4% | 17.1% | ||
| Q2 25 | -3.9% | -9.5% | ||
| Q1 25 | -21.2% | 33.7% | ||
| Q4 24 | -11.2% | -28.8% | ||
| Q3 24 | -3.3% | -4.6% | ||
| Q2 24 | 2.1% | -5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 10.9% | ||
| Q3 25 | 16.0% | 10.1% | ||
| Q2 25 | 19.3% | 9.0% | ||
| Q1 25 | 22.7% | 17.0% | ||
| Q4 24 | 26.3% | 28.9% | ||
| Q3 24 | 23.3% | 22.4% | ||
| Q2 24 | 19.4% | 31.3% |
| Q1 26 | 13.78× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 4.43× | -0.31× | ||
| Q1 25 | 1.37× | 13.19× | ||
| Q4 24 | 3.58× | 0.01× | ||
| Q3 24 | 2.39× | — | ||
| Q2 24 | 2.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
ALB
| Energy Storage | $759.1M | 53% |
| Specialties | $348.9M | 24% |
| Ketjen | $320.1M | 22% |
